ACT-335827 | m-entrepreneurship.com

Product Name :
ACT-335827

Search keywords :
ACT-335827

drugId :
null

Target Vo:
Orexin receptor type 1

Target Vo Short Name :
OX1R

Moa_Name:
Orexin receptor type 1 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Actelion Pharmaceuticals Ltd

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Nervous System Diseases

Termination Status :
Phase 1 Clinical

China Termination Status :

Highest Status:
Pending

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Met (C-Met) Rabbit mAb Formula
E-Cadherin Rabbit mAb Protocol
APOA1 Antibody: APOA1 Antibody is an unconjugated, approximately 28 kDa, rabbit-derived, anti-APOA1 polyclonal antibody. APOA1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, rat, chicken, and predicted: pig, cow background without labeling.

Author: Betaine hydrochloride

Related Posts